Measles-mumps-rubella-varicella combination vaccine (ProQuad): a guide to its use in children in the E.U.
In the EU, the live attenuated, tetravalent measles-mumps-rubella-varicella vaccine ProQuad is indicated for simultaneous vaccination against measles, mumps, rubella and varicella in individuals from 12 months of age using a two-dose schedule and may be used in infants from 9 months of age to conform with a national vaccination schedule, outbreak situations or travel to a region with a high prevalence of measles. Clinical data in young children indicates that vaccination with ProQuad is as immunogenic as the component vaccines, provides long-term protection against these potentially serious childhood infections and has an acceptable safety profile. Combining the viral strains of the measles-mumps-rubella vaccine M-M-RVAXPRO and the varicella vaccine Varivax in ProQuad reduces the complexity of vaccination schedules, thereby potentially improving vaccination coverage and the timeliness of vaccination.
Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand, demail@springer.com.
Lesley J
LJ
Scott
D002644:Chickenpox / Q000517:prevention & control; D019433:Chickenpox Vaccine / Q000008:administration & dosage*; D002648:Child; D005062:European Union; D006801:Humans; D007115:Immunization Schedule; D007223:Infant; D008457:Measles / Q000517:prevention & control; D022542:Measles-Mumps-Rubella Vaccine / Q000008:administration & dosage*; D009107:Mumps / Q000517:prevention & control; D012409:Rubella / Q000517:prevention & control; D014611:Vaccination; D017778:Vaccines, Combined / Q000008:administration & dosage
D019433:Chickenpox Vaccine; D022542:Measles-Mumps-Rubella Vaccine; D017778:Vaccines, Combined; C050102:measles, mumps, rubella, varicella vaccine